Dr. Ferrari on LBH589 and Bicalutamide in CRPC

Anna C. Ferrari, MD
Published: Friday, Oct 02, 2015



Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), NYU Langone Medical Center, discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer (CRPC).

Patients enrolled in the study previously failed at least two hormonal manipulations. More than 75% were metastatic, Ferrari says. Patients received the combination at two dose levels to compare efficacy and toxicities. There were no fatalities, but some patients did experience grade 3/4 adverse events. Grade 2/3 events included fatigue and gastrointestinal effects, Ferrari adds.

Nine of 21 patients received the treatment for up to 6 months, while a smaller subset received the combination for up to 27 months without evidence of radiographic progression.



Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), NYU Langone Medical Center, discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer (CRPC).

Patients enrolled in the study previously failed at least two hormonal manipulations. More than 75% were metastatic, Ferrari says. Patients received the combination at two dose levels to compare efficacy and toxicities. There were no fatalities, but some patients did experience grade 3/4 adverse events. Grade 2/3 events included fatigue and gastrointestinal effects, Ferrari adds.

Nine of 21 patients received the treatment for up to 6 months, while a smaller subset received the combination for up to 27 months without evidence of radiographic progression.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x